Autopsy report · NCT02546986
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
Cause of deathNo reason given
Life of this trial
- Registered 2 months before it started.
- Ran for about 9 years 9 months before it stopped.
- 100 participants enrolled.
- Results were posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Celgene
- Sponsor type
- Industry
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- CC-486; Pembrolizumab; Placebo
- Participants
- 100
- Sites
- 33
- Countries
- France, Germany, Greece, Italy, Spain, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.